Patents by Inventor Alan Duncan Robertson
Alan Duncan Robertson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230257342Abstract: The present invention relates to novel compounds which are capable of inhibiting semicarbazide-sensitive amine oxidase (SSAO/VAP-1) and monoamine oxidase B (MAO-B). These compounds are useful for treatment of a variety of neuromuscular diseases, such as muscular dystrophies, and neuroinflammatory diseases, including both peripheral and central disorders in human subjects, as well as in pets and livestock. In addition, the present invention relates to pharmaceutical compositions containing these compounds, as well as various uses thereof.Type: ApplicationFiled: June 25, 2021Publication date: August 17, 2023Inventors: Alan Duncan Robertson, Alison Dorothy Findlay, Alberto Buson, Craig Ivan Turner, Dieter Wolfgang Hamprecht, Jonathan Stuart Foot, Mandar Deodhar, Wolfgang Jarolimek, Serena Becchi, Bernard Walter Balleine, Marcella Canton, Libero Vitiello, Bert Blaauw
-
Patent number: 11098045Abstract: The present invention relates to novel compounds which are capable of inhibiting certain amine oxidase enzymes. These compounds are useful for treatment of a variety of indications, e.g., fibrosis, cancer and/or angiogenesis in human subjects as well as in pets and livestock. In addition, the present invention relates to pharmaceutical compositions containing these compounds, as well as various uses thereof.Type: GrantFiled: June 11, 2020Date of Patent: August 24, 2021Assignee: Pharmaxis Ltd.Inventors: Alison Dorothy Findlay, Craig Ivan Turner, Mandar Deodhar, Jonathan Stuart Foot, Wolfgang Jarolimek, Wenbin Zhou, Alan Duncan Robertson
-
Publication number: 20200317666Abstract: The present invention relates to novel compounds which are capable of inhibiting certain amine oxidase enzymes. These compounds are useful for treatment of a variety of indications, e.g., fibrosis, cancer and/or angiogenesis in human subjects as well as in pets and livestock. In addition, the present invention relates to pharmaceutical compositions containing these compounds, as well as various uses thereof.Type: ApplicationFiled: June 11, 2020Publication date: October 8, 2020Applicant: PHARMAXIS LTD.Inventors: Alison Dorothy Findlay, Craig Ivan Turner, Mandar Deodhar, Jonathan Stuart Foot, Wolfgang Jarolimek, Wenbin Zhou, Alan Duncan Robertson
-
Patent number: 10717733Abstract: The present invention relates to novel compounds which are capable of inhibiting certain amine oxidase enzymes. These compounds are useful for treatment of a variety of indications, e.g., fibrosis, cancer and/or angiogenesis in human subjects as well as in pets and livestock. In addition, the present invention relates to pharmaceutical compositions containing these compounds, as well as various uses thereof.Type: GrantFiled: February 10, 2017Date of Patent: July 21, 2020Assignee: Pharmaxis Ltd.Inventors: Alison Dorothy Findlay, Craig Ivan Turner, Mandar Deodhar, Jonathan Stuart Foot, Wolfgang Jarolimek, Wenbin Zhou, Alan Duncan Robertson
-
Patent number: 10717734Abstract: The present invention relates to novel compounds which are capable of inhibiting certain amine oxidase enzymes. These compounds are useful for treatment of a variety of indications, e.g., fibrosis, cancer and/or angiogenesis in human subjects as well as in pets and livestock. In addition, the present invention relates to pharmaceutical compositions containing these compounds, as well as various uses thereof.Type: GrantFiled: February 10, 2017Date of Patent: July 21, 2020Assignee: Pharmaxis Ltd.Inventors: Alison Dorothy Findlay, Craig Ivan Turner, Mandar Deodhar, Jonathan Stuart Foot, Wolfgang Jarolimek, Wenbin Zhou, Alan Duncan Robertson
-
Publication number: 20200069648Abstract: The present invention relates to novel compounds which are capable of inhibiting certain amine oxidase enzymes. These compounds are useful for treatment of a variety of indications, e.g., fibrosis, cancer and/or angiogenesis in human subjects as well as in pets and livestock. In addition, the present invention relates to pharmaceutical compositions containing these compounds, as well as various uses thereof.Type: ApplicationFiled: March 2, 2018Publication date: March 5, 2020Inventors: Alison Dorothy FINDLAY, Craig Ivan TURNER, Mandar DEODHAR, Jonathan Stuart FOOT, Wenbin ZHOU, Wolfgang JAROLIMEK, Alan Duncan ROBERTSON
-
Publication number: 20190119269Abstract: The present invention relates to novel compounds which are capable of inhibiting certain amine oxidase enzymes. These compounds are useful for treatment of a variety of indications, e.g., fibrosis, cancer and/or angiogenesis in human subjects as well as in pets and livestock. In addition, the present invention relates to pharmaceutical compositions containing these compounds, as well as various uses thereof.Type: ApplicationFiled: February 10, 2017Publication date: April 25, 2019Applicant: PHARMAXIS LTD.Inventors: Alison Dorothy Findlay, Craig Ivan Turner, Mandar Deodhar, Jonathan Stuart Foot, Wolfgang Jarolimek, Wenbin Zhou, Alan Duncan Robertson
-
Publication number: 20190071396Abstract: The present invention is related to the preparation and pharmaceutical use of substituted 3-haloallylamine derivatives as SSAO/VAP-1 inhibitors having the structure of Formula I, as defined in the specification: The invention also relates to methods of using compounds of Formula I, or pharmaceutically acceptable salt or derivatives thereof, for the treatment of a variety of indications, e.g., inflammatory diseases, ocular diseases, fibrotic diseases, diabetes-induced diseases and cancer.Type: ApplicationFiled: November 1, 2018Publication date: March 7, 2019Inventors: Mandar Deodhar, Alison Dorothy Findlay, Jonathan Stuart Foot, Wolfgang Jarolimek, Ian Alexander Mcdonald, Alan Duncan Robertson, Craig Ivan Turner
-
Publication number: 20190040007Abstract: The present invention relates to novel compounds which are capable of inhibiting certain amine oxidase enzymes. These compounds are useful for treatment of a variety of indications, e.g., fibrosis, cancer and/or angiogenesis in human subjects as well as in pets and livestock. In addition, the present invention relates to pharmaceutical compositions containing these compounds, as well as various uses thereof.Type: ApplicationFiled: February 10, 2017Publication date: February 7, 2019Applicant: PHARMAXIS LTD.Inventors: Alison Dorothy Findlay, Craig Ivan Turner, Mandar Deodhar, Jonathan Stuart Foot, Wolfgang Jarolimek, Wenbin Zhou, Alan Duncan Robertson
-
Patent number: 10160723Abstract: The present invention is related to the preparation and pharmaceutical use of substituted 3-haloallylamine derivatives as SSAO/VAP-1 inhibitors having the structure of Formula I, as defined in the specification: The invention also relates to methods of using compounds of Formula I, or pharmaceutically acceptable salt or derivatives thereof, for the treatment of a variety of indications, e.g., inflammatory diseases, ocular diseases, fibrotic diseases, diabetes-induced diseases and cancer.Type: GrantFiled: October 5, 2017Date of Patent: December 25, 2018Assignee: Boehringer Ingelheim International GmbHInventors: Mandar Deodhar, Alison Dorothy Findlay, Jonathan Stuart Foot, Wolfgang Jarolimek, Ian Alexander Mcdonald, Alan Duncan Robertson, Craig Ivan Turner
-
Publication number: 20180086698Abstract: The present invention is related to the preparation and pharmaceutical use of substituted 3-haloallylamine derivatives as SSAO/VAP-1 inhibitors having the structure of Formula I, as defined in the specification: The invention also relates to methods of using compounds of Formula I, or pharmaceutically acceptable salt or derivatives thereof, for the treatment of a variety of indications, e.g., inflammatory diseases, ocular diseases, fibrotic diseases, diabetes-induced diseases and cancer.Type: ApplicationFiled: October 5, 2017Publication date: March 29, 2018Inventors: Mandar Deodhar, Alison Dorothy Findlay, Jonathan Stuart Foot, Wolfgang Jarolimek, Ian Alexander Mcdonald, Alan Duncan Robertson, Craig Ivan Turner
-
Patent number: 9815782Abstract: The present invention is related to the preparation and pharmaceutical use of substituted 3-haloallylamine derivatives as SSAO/VAP-1 inhibitors having the structure of Formula I, as defined in the specification: The invention also relates to methods of using compounds of Formula I, or pharmaceutically acceptable salt or derivatives thereof, for the treatment of a variety of indications, e.g., inflammatory diseases, ocular diseases, fibrotic diseases, diabetes-induced diseases and cancer.Type: GrantFiled: February 26, 2016Date of Patent: November 14, 2017Assignee: Boehringer Ingelheim International GmbHInventors: Mandar Deodhar, Alison Dorothy Findlay, Jonathan Stuart Foot, Wolfgang Jarolimek, Ian Alexander Mcdonald, Alan Duncan Robertson, Craig Ivan Turner
-
Publication number: 20160244406Abstract: The present invention is related to the preparation and pharmaceutical use of substituted 3-haloallylamine derivatives as SSAO/VAP-1 inhibitors having the structure of Formula I, as defined in the specification: The invention also relates to methods of using compounds of Formula I, or pharmaceutically acceptable salt or derivatives thereof, for the treatment of a variety of indications, e.g., inflammatory diseases, ocular diseases, fibrotic diseases, diabetes-induced diseases and cancer.Type: ApplicationFiled: February 26, 2016Publication date: August 25, 2016Applicant: Boehringer Ingelheim International GmbHInventors: Mandar Deodhar, Alison Dorothy Findlay, Jonathan Stuart Foot, Wolfgang Jarolimek, Ian Alexander Mcdonald, Alan Duncan Robertson, Craig Ivan Turner
-
Patent number: 9302986Abstract: The preparation and pharmaceutical use of substituted 3-haloallylamine derivatives as SSAO/VAP-1 inhibitors having the structure of Formula I: is described. Methods of using compounds of Formula I, or pharmaceutically acceptable salt or derivatives thereof, for the treatment of a variety of indications, e.g., inflammatory diseases, ocular diseases, fibrotic diseases, diabetes-induced diseases and cancer, are also described.Type: GrantFiled: April 5, 2013Date of Patent: April 5, 2016Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Mandar Deodhar, Alison Dorothy Findlay, Jonathan Stuart Foot, Wolfgang Jarolimek, Ian Alexander Mcdonald, Alan Duncan Robertson, Craig Ivan Turner
-
Patent number: 7037907Abstract: A conjugated prodrug of an estradiol compound conjugated to a biological activity modifying agent.Type: GrantFiled: October 13, 2000Date of Patent: May 2, 2006Assignee: The University of MelbourneInventors: Alastair George Stewart, David James McAllister, Maree Patricia Collis, Alan Duncan Robertson
-
Patent number: 6930118Abstract: The invention provides aminoalkylindole compounds of Formula (I), wherein R1-R5, n and p are as described. Also provided are compositions containing compounds of Formula (I) and the use of compounds of Formula (I) in modulating the activity of a cannabinoid receptor in a subject.Type: GrantFiled: November 2, 2001Date of Patent: August 16, 2005Assignee: Amrad Operations Pty. Ltd.Inventors: Peter Gerard Moloney, Alan Duncan Robertson
-
Patent number: 6881740Abstract: This invention relates to compounds to formula (1) wherein B is optionally substituted aryl; R1 and R2 are the same or different and are independently selected from hydrogen or C1-3 alkyl; n is 1 or 2, preferably n is 1; m is 0 or 1; R3 is hydrogen or acyl, R4 and R5 are the same or different and are independently selected from amino, alkylamino, dialkylamino, arylamino and C2-C4 cycloalkylamino; X and Y are independently selected from C, H or N provided at least one of X and Y is N; and salts thereof, solvates thereof, pharmaceutically acceptable derivatives thereof, prodrugs thereof, tautomers thereof and/or isomers thereof, and processes for their reparation and methods of treatment, pharmaceutical formulations and uses involving them.Type: GrantFiled: July 8, 1999Date of Patent: April 19, 2005Assignee: Monash UniversityInventors: Bevyn Jarrott, Phillip Mark Beart, William Roy Jackson, Alan Duncan Robertson, Maree Patricia Collis, Alexandra Papanikos
-
Publication number: 20040034073Abstract: The invention provides aminoalkylindole compounds of Formula (I), wherein R1-R5, n and p are as described. Also provided are compositions containing compounds of Formula (I) and the use of compounds of Formula (I) in modulating the activity of a cannabinoid receptor in a subject. In particular, the invention provides the use of such compounds as analgesic agents.Type: ApplicationFiled: August 22, 2003Publication date: February 19, 2004Inventors: Peter Gerard Moloney, Alan Duncan Robertson
-
Patent number: 6232314Abstract: Arylalkylpiperazine compounds (1) wherein B is aryl or optionally substituted aryl; R1 is hydroxy; R2 and R3 are the same or different and are independently selected from hydrogen or C1-3 alkyl; m is 0, 1 or 2; D is a linking chain of atoms which may be optionally substituted and which contains from 1 to 8 atoms in the chain; E is a phenolic antioxidant group or a corresponding amino derivative thereof wherein the phenolic hydroxyl is replaced by amino, are disclosed. The compounds have both free radical scavenging activity and block excitatory amino acid activity. Some compounds of the present invention also display an affinity for voltage-sensitive sodium channels.Type: GrantFiled: March 18, 1999Date of Patent: May 15, 2001Assignee: Monash UniversityInventors: Bevyn Jarrott, Philip Mark Beart, William Roy Jackson, Vijaya Bhaskar Kenche, Alan Duncan Robertson, Maree Patricia Collis